Table 1.

Considerations for therapeutic management of nonhospitalized adults with cancer and mild to moderate COVID-19 without hypoxia

Supportive and symptomatic management	As per standard of care
Anti–SARS-CoV-2 monoclonal antibodies	Bebtelovimab within 7 d after symptom onset, as it retains activity against B.1.1.529 (ο) and its BA.1 and BA.2 variants (evidence of in vitro activity against SARS-CoV-2, but no clinical efficacy data from placebo-controlled trials. Consider as alternative therapy when preferred therapies are not available.
Antiviral agents	5 d of ritonavir-boosted nirmatrelvir within 5 d of symptom onset (preferred agent with careful consideration for drug-drug interactions)
	3 d of IV remdesivir within 7 d of symptom onset (preferred agent but logistically challenging)
	5 d of molnupiravir within 5 d of symptom onset (alternative therapy when preferred therapies are not available)
Systemic steroids	No benefit of systemic steroids (including dexamethasone) in nonhospitalized patients and in the absence of another indication